Практические аспекты лечения рецидивов BRCA-ассоциированного рака яичников

СтатьяМЕД СОВЕТ. 2019; № 19: 144–149. DOI:10.21518/2079-701X-2019-19-144-149

Румянцев А.А.^[1]

Тюляндина А.С.^[1]

^[1]НИИ клинической онкологии имени академика РАН и РАМН Н.Н. Трапезникова, Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина

олапариб

рак яичников

химиотерапия

BRCA

рецидив рака яичников

платиновые препараты

Новообразования

Рецидив

Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 250 c. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf. Последний доступ 08.10.2019.http://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf

Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с. Режим доступа: http://www.oncology.ru/service/statistics/condition/2018.pdf. Последний доступ: 05.10.2019.http://www.oncology.ru/service/statistics/condition/2018.pdf

Stratton J.F., Pharoah P., Smith S.K., Easton D., Ponder B.A.J. A systematic review and metaanalysis of family history and risk of ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology. 1998;105(5):493-499. doi: 10.1111/j.1471-0528.1998.tb10148.x..
DOI: 10.1111/j.1471-0528.1998.tb10148.x

Tyulyandina A., Gorbunova V., Khokhlova S., et al. Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study. AACR Annual Meeting. 2018; April 14-18, 2018. doi: 10.1158/1538-7445.AM2018-1241..
DOI: 10.1158/1538-7445.AM2018-1241

Soegaard M., Kjaer S.K., Cox M., et al. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research. 2008;14(12):3761-3767. doi: 10.1158/1078-0432.CCR-07-4806..
DOI: 10.1158/1078-0432.CCR-07-4806

George A., Kaye S., Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature Reviews Clinical Oncology. 2017;14(5):284-296. doi: 10.1038/nrclinonc.2016.191..
DOI: 10.1038/nrclinonc.2016.191

Møller P., Hagen A.I., Apold J., et al. Genetic epidemiology of BRCA mutations – family history detects less than 50[%] of the mutation carriers. European Journal of Cancer. 2007;43(11):1713-1717. doi: 10.1016/j.ejca.2007.04.023.
DOI: 10.1016/j.ejca.2007.04.023

Alsop K., Fereday S., Meldrum C., et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2012;30(21):2654-2663. doi: 10.1200/JCO.2011.39.8545..
DOI: 10.1200/JCO.2011.39.8545

Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian Cancer Risk in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations. Clin Cancer Res. 2002;8(12):3776-3781.

Yun M.H., Hiom K. Understanding the functions of BRCA1 in the DNA-damage response. Biochemical Society Transactions. 2009;37(3):597-604. doi: 10.1042/BST0370597..
DOI: 10.1042/BST0370597

Ashworth A. A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair. Journal of Clinical Oncology. 2008;26(22):3785-3790. doi: 10.1200/JCO.2008.16.0812..
DOI: 10.1200/JCO.2008.16.0812

Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D’Andrea A.D. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discovery. 2015;5(11):1137-1154. doi: 10.1158/2159-8290.CD-15-0714..
DOI: 10.1158/2159-8290.CD-15-0714

Mirza M.R., Monk B.J., Herrstedt J., et al. Niraparib Maintenance Therapy in PlatinumSensitive, Recurrent Ovarian Cancer. New England Journal of Medicine. 2016;375(22):2154-2164. doi: 10.1056/NEJMoa1611310..
DOI: 10.1056/NEJMoa1611310

Coleman R.L., Oza A.M., Lorusso D., et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet. 2017;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6..
DOI: 10.1016/S0140-6736(17)32440-6

Pujade-Lauraine E., Ledermann J.A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-сontrolled, phase 3 trial. The Lancet Oncology. 2017;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2..
DOI: 10.1016/S1470-2045(17)30469-2

Ledermann J., Harter P., Gourley C., et al. Olaparib Maintenance Therapy in PlatinumSensitive Relapsed Ovarian Cancer. New England Journal of Medicine. 2012;366(15):1382-1392. doi:10.1056/NEJMoa1105535..
DOI: 10.1056/NEJMoa1105535

McNeish I.A., Ledermann J.A., Webber L., et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Annals of Oncology. 2014;25(10):1988-1995. doi: 10.1093/annonc/mdu363..
DOI: 10.1093/annonc/mdu363

Ledermann J.A., Harter P., Gourley C., et al. Overall survival in patients with platinumsensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Oncology. 2016;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X..
DOI: 10.1016/S1470-2045(16)30376-X

Friedlander M., Matulonis U., Gourley C., et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer. 2018;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y..
DOI: 10.1038/s41416-018-0271-y

Ledermann J., Harter P, Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 2014;15(8):852-861. doi: 10.1016/S1470-2045(14)70228-1..
DOI: 10.1016/S1470-2045(14)70228-1

Любченко Л.Н., Батенева Е.И., Абрамов И.С. и соавт. Наследственный рак молочной железы и яичников. Злокачественные опухоли. 2013;(2):53-61. doi: 10.18027/2224-5057-2013-2-53-61..
DOI: 10.18027/2224-5057-2013-2-53-61

Plon S.E., Eccles D.M., Easton D., et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human Mutation. 2008;29(11):1282-1291. doi: 10.1002/humu.20880..
DOI: 10.1002/humu.20880

Kolor K., Chen Z., Grosse S.D., et al. BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas – United States, 2009–2014. MMWR Surveillance Summaries. 2017;66(15):1-11. doi: 10.15585/mmwr.ss6615a1..
DOI: 10.15585/mmwr.ss6615a1

Cline M.S., Babbi G., Bonache S., et al. Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants. Human Mutation. 2019;40(9):1546-1556. doi: 10.1002/humu.23861..
DOI: 10.1002/humu.23861

Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. Journal of Clinical Oncology. 2002;20(6):1480-1490. doi: 10.1200/JCO.2002.20.6.1480..
DOI: 10.1200/JCO.2002.20.6.1480

Gunderson C.C., Matulonis U., Moore K.N. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecologic Oncology. 2018;148(3):591-600. doi: 10.1016/j.ygyno.2018.01.010..
DOI: 10.1016/j.ygyno.2018.01.010

Friedlander M., Gebski V., Gibbs E., et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinumsensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. The Lancet Oncology. 2018;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7..
DOI: 10.1016/S1470-2045(18)30343-7

Robson M.E., Tung N., Conte P., et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology. 2019;30(4):558-566. doi: 10.1093/annonc/mdz012.
DOI: 10.1093/annonc/mdz012

Язык текста: Русский

ISSN: 2079-701X